With 80 appearances under his belt, Sidley Austin’s Carter Phillips claims to hold the title for most U.S. Supreme Court arguments by a private lawyer. But he won’t have a chance to argue for Gilead Sciences Inc., after the high court declined to consider whether an appeals panel unfairly left the company at risk of losing nearly two years of patent protection on the much-hyped influenza drug Tamiflu.
The justices rejected Phillips’ cert petition on Monday, refusing to wade into in a patent dispute between Gilead and Natco Pharma Ltd. Natco, an Indian company that is looking to produce a generic version of Tamiflu, initially sought approval for its drug in 2011. Gilead and Hoffmann-La Roche Inc., which sells Tamiflu under a license from Gilead, fired back with patent infringement claims the same year.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
